![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2021
Schoffski, Patrick; Kubickova, Michaela; Wozniak, Agnieszka; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Switaj, Tomasz; Bucklein, Veit; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Lee, Che-Jui; Speetjens, Frank M.; Nzokirantevye, Axelle; Neven, Anouk und Kasper, Bernd
(2021):
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
In: European Journal of Cancer, Bd. 156: S. 12-23
2018
Schoffski, Patrick; Sufliarsky, Jozef; Gelderblom, Hans; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Rutkowski, Piotr; Lindner, Lars H.; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Cann, Thomas van; Marreaud, Sandrine; Nzokirantevye, Axelle; Collette, Sandra und Wozniak, Agnieszka
(2018):
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
In: Lancet Respiratory Medicine, Bd. 6, Nr. 6: S. 431-441